The company has today announced that it is considering an initial public offerings, with intentions to publish a registration document today.
The company has commented that the offer would consist of a secondary sell-down of existing ordinary shares by certain existing shareholders including IngreLux. Following admission, the company would have a free float of around 25 per cent of issued share capital.
Paul Mason, Chairman of Dr. Martens, commented: “Today marks an important milestone for Dr. Martens and is testament to the skills and hard work of our management team, as we build the business to match the scale and potential of our brand.
We have made significant investment in the business over the last few years to strengthen the team, our operations and position ourselves for the next exciting stage of development, as a publicly listed company.”
